BRAIN and NERVE－神経研究の進歩73巻1号

2021年01月発行

特集 Neuro-Oncology

抗がん剤と神経系

著者： 福武敏夫¹

所属機関： ¹亀田メディカルセンター脳神経内科

ページ範囲：P.21 - P.33

文献概要

本論文では，伝統的な細胞毒性による化学療法や生物学的製剤および分子標的薬を含む抗がん剤治療における末梢および中枢神経系毒性の臨床的様相と部分的に治療について概観する。新規の免疫治療［免疫チェックポイント阻害薬とキメラ抗原受容体T細胞（CAR-T）治療］には触れない。化学療法の神経学的合併症は患者に強い障害を起こすが，抗がん治療を受ける患者の生存期間が長くなり，複雑なレジメンを長い治療期間にわたって受けることから，その頻度は高くなってきている。責任薬剤の中止や用量の見直しによってさらなるあるいは永続的な神経障害を避けうるので，脳神経内科医を含む臨床医は治療関連の神経毒性についてよく知るべきである。

参考文献

1)福武敏夫: 市中総合病院におけるGeneral Neurology. 教育コース40: 神経診察におけるgeneral neurologyの重要性. 第57回日本神経学会学術大会, 2016

2)西村寿貴, 松平敬史, 荒木邦彦, 高橋正年, 片多史明, 他: 基幹病院における院内発症脳梗塞の臨床的検討. 脳卒中33: 374-377, 2011

3)Santomasso BD: Anticancer drugs and the nervous system. Continuum 26: 732-764, 2020

4)Graber JJ, DeAngelis LM: Central nervous system toxicity of chemotherapy. Wen PY, Schiff D, Lee EQ (eds): Neurologic Complications of Cancer Therapy. Demos Medical, New York, 2012, pp213-235

5)Wick W, Hertenstein A, Platten M: Neurological sequelae of cancer immunotherapies and targeted therapies. Lancet Oncol 16: e529-e541, 2016［doi: 10.1016/s1470-2045(16)30571-x］

6)岡元るみ子, 佐々木常雄（編）: がん化学療法副作用対策ハンドブック, 第3版. 羊土社, 東京, 2020

7)日本臨床腫瘍薬学会（監）, 遠藤一司, 加藤裕芳, 松井礼子（編）: がん化学療法レジメンハンドブック, 第6版. 羊土社, 東京, 2020

8)楠　淳一, 齋藤豊和: 抗悪性腫瘍薬による末梢神経障害. Brain Nerve 60: 131-136, 2008

9)Molassiotis A, Cheng HL, Lopez V, Au JSK, Chan A, et al: Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy. BMC Cancer 19: 132, 2019

10)Kuncl RW, George EB: Toxic neuropathies and myopathies. Curr Opin Neurol 6: 695-704, 1993

11)Ibañez-Juliá MJ, Berzero G, Reyes-Botero G, Maisonobe T, Lenglet T, et al: Antineoplastic agents exacerbating Charcot Marie Tooth disease: red flags to avoid permanent disability. Acta Oncol 57: 403-411, 2018

12)Cavaletti G, Marmironi P: Chemotherapy induced peripheral neurotoxicity. Nat Rev Neurol 6: 657-666, 2010

13)Cavaletti G, Marmironi P: Neurologic complications affecting peripheral nerves. Wen PY, Schiff D, Lee EQ (eds): Neurologic Complications of Cancer Therapy. Demos Medical, New York, 2012, pp237-261

14)Heinzerling L, Eigentler TK, Fluck M, Hassel JC, Heller-Schenck D, et al: Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management. ESMO Open 4: e000491, 2019［doi: 10.1136/esmoopen-2019-000491］

15)Pentsova E, Liu A, Rosenblum M, O'Reilly E, Chen X, et al: Gemcitabine induced myositis in patients with pancreatic cancer: case reports and topic review. J Neurooncol 106: 15-21, 2012

16)Chen X, Schwartz GK, DeAngelis LM, Kely T, Carvajal RD: Dropped head syndrome: report of three cases during treatment with a MEK inhibitor. Neurology 79: 1929-1931, 2012

17)Solak Y, Dikbas O, Altundag K, Guler N, Ozisik Y: Myasthenic crisis following cisplatin chemotherapy in a patient with malignant thymoma. J Exp Clin Cancer Res 23: 343-344, 2004

18)Rohde D, Sliwka U, Schweizer K, Jakse G: Oculo-bulbar myasthenia gravis induced by cytokine treatment of a patient with metastasized renal cell carcinoma. Eur J Clin Pharmacol 50: 471-473, 1996

19)Wefel JS, Lenzi R, Theriault R, Buzdar AU, Crruickshank S, et al: 'Chemobrain' in breast carcinoma?: a prologue. Cancer 101: 466-475, 2004

20)Soffietti R, Trevisan E, Rudà R: Neurologic complications of chemotherapy and other newer and experimental approaches. Biller J, Ferro JM (eds): Neurologic Aspects of Systemic Disease, Part III. Elsevier, Edinburgh, 2014, pp1199-1218

21)Pfeiffer P, Nielsen D, Yilmaz M, Iversen A, Vejlø C, et al: Cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure of irinotecan, oxaliplatin and 5-fluorouracil. Acta Oncol 46: 697-701, 2007

22)Avila EK, Graber J: Seizures and epilepsy in cancer patients. Curr Neurol Neurosci Rep 10: 60-67, 2010

23)Zito JA, Lee CC, Johnson S, Singer J, Vacirca J: Reversible posterior leukoencephalopathy syndrome after rituximab. Am J Emerg Med 28: 537, 2010［doi: 10.1016/j.ajem.2009.04.019］

24)Vaughn C, Zhang L, Schiff D: Reversible posterior leukoencephalopathy syndrome in cancer. Curr Oncol Rep 10: 86-91, 2008

25)Sul JK, DeAngelis LM: Neurologic complications of cancer chemotherapy. Semin Oncol 33: 324-332, 2006

26)Eberly AL, Anderson GD, Bubalo JS, McCune JS: Optimal prevention of seizures induced by high-dose busulfan. Pharmacotherapy 28: 1502-1510, 2008

27)Baker WJ, Royer GL, Weiss RB: Cytarabine and neurologic toxicity. J Clin Oncol 9: 679-693, 1991

28)Kishi S, Griener J, Cheng C, Das S, Cook EH, et al: Homocysteine, pharmacogenesis, and neurotoxicity in children with leukemia. J Clin Oncol 21: 3084-3091, 2003

29)Myers JS: Chemotherapy-related cognitive impairment. Clin J Oncol Nurs 13: 413-421, 2009

30)Matsos A, Loomes M, Zhou I, Macmillan E, Sabel I, et al: Chemotherapy-induced cognitive impairments: white matter pathogenesis. Cancer Treat Rev 61: 6-14, 2017

31)Boogerd W, vd Sande JJ, Moffie D: Acute fever and delayed leukoencephalopathy following low dose intraventricular methotrexate. J Neurol Neurosurg Psychiatry 51: 1277-1283, 1988

32)Perry A, Schmidt RE: Cancer therapy-associated CNS neuropathology: an update and review of the literature. Acta Neuropathol 111: 197-212, 2006

33)Li SH, Chen WH, Tang Y, Rau K-M, Chen Y-Y, et al: Incidence of ischemic stroke post-chemotherapy: a retrospective review of 10,963 patients. Clin Neurol Neurosurg 108: 150-156, 2006

34)Içli F, Karaoğuz H, Dinçol D, Demirkazik A, Günel N, et al: Severe vascular toxicity associated with cisplatin-based chemotherapy. Cancer 72: 587-593, 1993

35)Numico G, Garrone O, Dongiovanni V, Silvestris N, Colantonio I, et al: Prospective evaluation of major vascular events in patients with non-small cell lung cancer treated with cisplatin and gemcitabine. Cancer 103: 994-999, 2005

36)Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS,et al: Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP study of tamoxifen and raloxifene (STAR) P-2 trial. JAMA 295: 2727-2741, 2006

37)Lubiniecki GM, Berlin JA, Weinstein RB, Vaughn DJ: Thromboembolic events with estramustine phosphate-based chemotherapy in patients with hormone-refractory prostate carcinoma: results of meta-analysis. Cancer 101: 2755-2759, 2004

38)Scappaticci FA, Skillings JR, Holden SN, Gerber H-P, Miller K, et al: Arterial thromboembolic events with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 99: 1232-1239, 2007

39)Rieger J, Bahr O, Muller K, Franz K, Steinbach J, et al: Bevacizumab-induced diffusion-restricted lesions in malignant glioma patients. J Neurooncol 99: 49-56, 2009

40)Besse B, Lasserre SF, Comptom P, Huang J, Augustus S, et al: Bevacizumab safety in patients with central nervous system metastases. Clin Cancer Res 16: 269-278, 2010

41)Kang TY, Jin T, Elinzano H, Peereboom D: Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety. Neurooncol 89: 113-118, 2008

42)Nghiemphu PL, Green RM, Pope WB, Lai A, Cloughesy TF: Safety of anticoagulation use and bevacizumab in patients with glioma. Neurooncol 10: 355-360, 2008

43)Taillibert S, Vincent LA, Granger B, Marie Y, Carpentier C, et al: Bevacizumab and irinotecan for recurrent oligodendroglial tumors. Neurology 72: 1601-1606, 2009

44)Chutorian AM, Bojko A, Heier L, Frucht S, Nygaard T, et al: Toxic pediatric parkinsonism: report of a child with metabolic studies and response to treatment. J Child Neurol 18: 812-815, 2003

45)Crystal SC, Leonidas J, Jakubowski A, Di Rocco A: Tahlidomide induced acute worsening of Parkinson's disease. Mov Disord 24: 1863-1864, 2009

46)Taieb S, Trillet-Lenoir V, Rambaud L, Descos L, Freyer G: Lhermitte sign and urinary retention: atypical presentation of oxaliplatin neurotoxicity in four patients. Cancer 94: 2434-2440, 2002

47)Liao B, Shroff S, Kamiya-Matsuoka C, Tummala S: Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro Oncol 16: 589-593, 2014

48)Mounier NM, Abdel-Maged AE, Wahdan SA, Gad AM, Azab SS: Chemotherapy-induced cognitive impairment (CICI): an overview of etiology and pathogenesis. Life Sci 258: 118071, 2020［doi: 10.1016/j.lfs.2020.118071］

49)Sittl R, Lampert A, Hurth T, Schuy ET, Link AS , et al: Anticancer drug oxaliplatin induces acute cooling-aggravated neuropathy via sodium channel subtype Na(V)1.6-resurgent and persistent current. Proc Natl Acad Sci U S A 109: 6704-6709, 2012

50)Cavaletti G, Bogliun G, Zincone A, Marzorati L, Melzi P, et al: Neuro- and ototoxicity of high-dose carboplatin treatment in poor prognosis ovarian cancer patients. Anticancer Res 18: 3797-3802, 1998

51)Loprinzi CL, Reeves BN, Dakhil SR, Sloan JA, Wolf SL, et al: Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1. J Clin Oncol 29: 1472-1478, 2011

52)Richardson PG, Briemberg H, Jagannath S, wen PY, Barlogie B, et al: Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 24: 3113-3120, 2006

53)Farquhar-Smith P: Chemothearpy-induced neuropathic pain. Curr Opin Support Palliat Care 5: 1-7, 2011

54)Kumar SK, Laubach JP, GioveTJ, Quick M, Neuwirth R, et al: Impact of concomitant dexamethasone dosing schedule on bortezomib-induced peripheral neuropathy in multiple myeloma. Br J Haematol 178: 756-763, 2017

55)Mileshkin L, Stark R, Day B, Seymour JF, Zeldis JB, et al: Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol 24: 4507-4514, 2006

56)Briani C, Zara G, Rondinone R, Iaccarino L, Ruggero S, et al: Positive and negative effects of thalidomide on refractory cutaneous lupus erythematosus. Autoimmunity 38: 549-555, 2005

57)Chaudhry V, Cornblath DR, Polydefkis M, Ferguson A, Borrello I: Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy. J Peripher Nerv Syst 13: 275-282, 2008

58)Takimoto CH, Lu ZH, Zhang R, Liang MD, Larson LV, et al: Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency. Clin Cancer Res 2: 477-481, 1996

59)Pirzada NA, Ali II, Dafer RM: Fluorouracil-induced neurotoxicity. Ann Pharmacother 34: 35-38,2000

60)福本竜也, 片多史明, 佐藤　進, 柴山秀博, 村山繁雄, 他: 5-fluorouracilとメトロニダゾールの併用にて急速進行性の白質脳症を呈した1例. 臨床神経58: 118-123, 2018

61)Vezmer S, Becker A, Bode U, Jaehde U: Biochemical and clinical aspects of methotrexate neurotoxicity. Chemotherapy 49: 92-104, 2003

62)Gosavi TD, Ahmad MT, Lee L-H, Lim S-H: Methotrexate induced leukoencephalopathy: a stroke mimic. Ann Indian Acad Neurol 16: 418-421, 2013

63)Kwong YL, Yeung DY, Chan JC: Intrathecal chemotherapy for hematologic malignancies: drugs and toxicities. Ann Hematol 88: 193-201, 2009

64)DeAngelis LM, Posner JB: Side effects of chemotherapy. DeAngelis LM, Posner JB (eds): Neurologic complications of cancer. 2nd ed. Oxford University Press, New York, 2009, pp447-510

65)Colvin LA: Chemotherapy-induced peripheral neuropathy (CIPN): where are we now? Pain 160(Suppl 1): S1-S10, 2019